Title |
Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8+ T-cell immunity against respiratory syncytial virus infection |
Author |
Jeong-Yoon Lee and Jun Chang* |
Address |
Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea |
Bibliography |
Journal of Microbiology, 55(11),900-908, 2017,
|
DOI |
10.1007/s12275-017-7306-6
|
Key Words |
recombinant baculovirus, respiratory syncytial
virus, m2 protein, cd8 t cells, vaccine |
Abstract |
Respiratory syncytial virus (RSV) is an important cause of
acute lower respiratory tract disease in infants, young children,
immunocompromised individuals, and the elderly. However,
despite ongoing efforts to develop an RSV vaccine, there
is still no authorized RSV vaccine for humans. Baculovirus
has attracted attention as a vaccine vector because of its ability
to induce a high level of humoral and cellular immunity, low
cytotoxicity against various antigens, and biological safety
for humans. In this study, we constructed a recombinant baculovirus-
based vaccine expressing the M2 protein of RSV under
the control of cytomegalovirus promoter (Bac_RSVM2)
to induce CD8+ T-cell responses which play an important
role in viral clearance, and investigated its protective efficacy
against RSV infection. Immunization with Bac_RSVM2 via
intranasal or intramuscular route effectively elicited the specific
CD8+ T-cell responses. Most notably, immunization with
Bac_RSVM2 vaccine almost completely protected mice from
RSV challenge without vaccine-enhanced immunopathology.
In conclusion, these results suggest that Bac_RSVM2 vaccine
employing the baculovirus delivery platform has promising
potential to be developed as a safe and novel RSV vaccine
that provides protection against RSV infection. |